Table 3. Product-specific COVID-19 vaccine effectiveness against SARS-CoV-2 infection by age group, dynamic cohort, Navarre, Spain, April–August 2021 (n = 30,240).

Study population and vaccination status	Cases/total	Secondary attack rate, %	Crude VE (95% CI)	Adjusted VE (95% CI)a
Close contacts 18–59 years old
Unvaccinated	4,386/13,114	33	Reference	Reference
1 dose of Janssen	180/892	20	40 (30 to 48)	52 (44 to 59)
1 dose of Spikevax	63/489	13	61 (51 to 70)	68 (58 to 75)
2 doses of Spikevax	65/912	7	79 (73 to 83)	83 (78 to 86)
1 dose of Comirnaty	291/1,738	17	50 (44 to 55)	60 (54 to 64)
2 doses of Comirnaty	743/5,863	13	62 (59 to 65)	70 (67 to 73)
1 dose of Vaxzevria	100/588	17	49 (38 to 58)	45 (33 to 55)
2 doses of Vaxzevria	148/808	18	45 (35 to 53)	54 (46 to 61)
1 dose of Vaxzevria +1 dose of Comirnaty	7/119	6	82 (63 to 92)	86 (70 to 93)
Close contacts ≥ 60 years old
Unvaccinated	425/1,234	34	Reference	Reference
1 dose of Janssen	29/105	28	20 (−17 to 45)	17 (−26 to 45)
1 dose of Spikevax	7/28	25	27 (−53 to 66)	25 (–59 to 65)
2 doses of Spikevax	20/215	9	73 (58 to 83)	68 (48 to 80)
1 dose of Comirnaty	60/284	21	39 (20 to 53)	32 (8 to 49)
2 doses of Comirnaty	327/2,109	16	55 (48 to 61)	50 (37 to 60)
1 dose of Vaxzevria	202/1,011	20	42 (31 to 51)	24 (3 to 40)
2 doses of Vaxzevria	124/731	17	51 (40 to 60)	44 (25 to 57)

CI: confidence interval; COVID-19: coronavirus disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VE: vaccine effectiveness.

^a VE adjusted by age group (18–34, 35–49, 50–69 and ≥ 70 years), sex, major chronic conditions, contact setting (household or other), month and vaccination status of index case.

These analyses estimate the VE by product, but product comparison may not be valid.